Topical composition and delivery system and its use
The described invention provides a topical delivery system comprising a pharmaceutical composition for application directly to a skin of a subject in need thereof comprising (a) an effective therapeutic amount of an active therapeutic agent; (b) chemical drivers comprising an amino benzoate local anesthetic, ethoxydiglycol and methylsulfonylmethane (MSM) that in combination are effective to synergistically deliver the therapeutic agent; and (c) a depot component for keeping the pharmaceutical composition in the skin. Methods for delivering an active therapeutic agent into skin, for keeping it in the skin, for reducing systemic side effects attributable to entry of the active agent into the blood stream, and a method for treating a condition, disease or disorder of skin topically also are described in accordance with the embodiments of the described invention.
1. A topical delivery system comprising a pharmaceutical composition formulated for application directly to a skin of a subject in need thereof comprising:
(a) a therapeutic amount of an amino benzoate local anesthetic agent;
(b) chemical drivers comprising ethoxydiglycol, propylene glycol and methylsulfonylmethane (MSM), wherein the chemical drivers are cooperatively effective to deliver the amino benzoate local anesthetic agent into skin;
(c) a depot component comprising a polymer for encapsulation of the pharmaceutical composition, and
(d) a stabilizer,
wherein the depot component keeps the active agent locally in the skin and reduces distribution of the active agent to the blood stream.
2. The topical delivery system according to claim 1 , wherein the depot component comprises an emollient and a surfactant.
3. The topical delivery system according to claim 2 , wherein the polymer is polyacrylamide (1-20% w/w), the emollient is C 13-14 isoparaffin (1-20% w/w), and the surfactant is laureth-7 (1-20% w/w).
4. The topical delivery system according to claim 3 , wherein the depot component is formed by the polyacrylamide polymer, the C 13-14 isoparaffin emollient and the laureth-7 surfactant.
5. The topical delivery system according to claim 1 , wherein the active therapeutic agent has a molecular weight below 500 Da.
6. The topical delivery system according to claim 1 , wherein the local anesthetic is selected from the group consisting of benzocaine, lidocaine, tetracaine or a combination thereof.
7. The topical delivery system according to claim 1 , wherein the pharmaceutical composition is in an administration form selected from the group consisting of a cream, gel, or a spray.
8. The topical delivery system according to claim 1 , further comprising a vasoconstrictor.
9. The topical delivery system according to claim 8 , wherein the vasoconstrictor is nonirritating when applied to skin.
10. A method of delivering a pharmaceutical composition topically that is effective to reduce systemic side effects of the active agent comprising:
(a) applying a pharmaceutical composition to a skin of a subject in need thereof, wherein the pharmaceutical composition comprises:
(i) a therapeutic amount of an amino benzoate local anesthetic agent;
(ii) chemical drivers comprising ethoxydiglycol, propylene glycol and methylsulfonylmethane (MSM), wherein the chemical drivers are cooperatively effective to deliver the amino benzoate local anesthetic agent into skin;
(iii) a depot component comprising a polymer, and
(iv) a stabilizer,
wherein the depot component encapsulates the pharmaceutical composition; keeps the aminobenzoate local anesthetic agent locally in the skin; and reduces distribution of the active agent to the blood stream.
11. The method according to claim 10 , wherein the depot component comprises an emollient and a surfactant.
12. The method according to claim 11 , wherein the polymer is polyacrylamide (1-20% w/w), the emollient is C 13-14 isoparaffin (1-20% w/w), and the surfactant is laureth-7 (1-20% w/w).
13. The method according to claim 12 , wherein the polyacrylamide polymer, the C 13-14 isoparaffin emollient and the laureth-7 surfactant form the depot component.
14. The method according to claim 10 , wherein the active therapeutic agent has a molecular weight below 500 Da.
15. The method according to claim 10 , wherein the amount of the therapeutic agent in the blood stream is less than a therapeutic amount.
16. The method according to claim 10 , wherein the depot component facilitates controlled or delayed type release of the active therapeutic agent.